- Home
- EVH vs DNLI Comparison
EVH vs DNLI Comparison
Compare EVH & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVH
- DNLI
- Stock Information
- Founded
- EVH 2011
- DNLI 2013
- Country
- EVH United States
- DNLI United States
- Employees
- EVH N/A
- DNLI N/A
- Industry
- EVH Other Consumer Services
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EVH Consumer Discretionary
- DNLI Health Care
- Exchange
- EVH Nasdaq
- DNLI Nasdaq
- Market Cap
- EVH 3.8B
- DNLI 4.5B
- IPO Year
- EVH 2015
- DNLI 2017
- Fundamental
- Price
- EVH $12.30
- DNLI $26.18
- Analyst Decision
- EVH Strong Buy
- DNLI Strong Buy
- Analyst Count
- EVH 10
- DNLI 11
- Target Price
- EVH $29.50
- DNLI $38.90
- AVG Volume (30 Days)
- EVH 3.3M
- DNLI 718.4K
- Earning Date
- EVH 11-07-2024
- DNLI 11-06-2024
- Dividend Yield
- EVH N/A
- DNLI N/A
- EPS Growth
- EVH N/A
- DNLI N/A
- EPS
- EVH N/A
- DNLI N/A
- Revenue
- EVH $2,464,254,000.00
- DNLI N/A
- Revenue This Year
- EVH $32.39
- DNLI N/A
- Revenue Next Year
- EVH $14.42
- DNLI $283.75
- P/E Ratio
- EVH N/A
- DNLI N/A
- Revenue Growth
- EVH 37.65
- DNLI 204.74
- 52 Week Low
- EVH $12.31
- DNLI $14.56
- 52 Week High
- EVH $35.00
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- EVH 22.64
- DNLI 45.97
- Support Level
- EVH $12.31
- DNLI $26.17
- Resistance Level
- EVH $15.56
- DNLI $33.33
- Average True Range (ATR)
- EVH 1.16
- DNLI 1.47
- MACD
- EVH -1.03
- DNLI 0.02
- Stochastic Oscillator
- EVH 1.74
- DNLI 23.65
About EVH Evolent Health Inc
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.